KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Non-Current Debt: 2024

Historic Non-Current Debt for Esperion Therapeutics (ESPR) over the last 1 years, with Dec 2024 value amounting to $141.0 million.

  • Esperion Therapeutics' Non-Current Debt was N/A to $151.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $151.7 million, marking a year-over-year change of. This contributed to the annual value of $141.0 million for FY2024, which is N/A change from last year.
  • Esperion Therapeutics' Non-Current Debt amounted to $141.0 million in FY2024.
  • Esperion Therapeutics' 5-year Non-Current Debt high stood at $141.0 million for FY2024, and its period low was $141.0 million during FY2024.
  • For the 1-year period, Esperion Therapeutics' Non-Current Debt averaged around $141.0 million, with its median value being $141.0 million (2024).